Division of Gastroenterology and Hepatology, Medical Spectrum Twente, Enschede, The Netherlands; Liver Transplantation, Mayo Clinic, Rochester, Minnesota, USA.
Obesity (Silver Spring). 2013 Sep;21(9):1935-41. doi: 10.1002/oby.20327. Epub 2013 May 29.
Allelic variation (rs738409C→G) in adiponutrin (patatin-like phospholipase domain-containing protein 3, PNPLA3) has been associated with hepatic steatosis and liver fibrosis. The physiologic impact of the PNPLA3 G allele may be exacerbated in patients with severe obesity. In this study, we investigated the interactions of PNPLA3 rs738409 with a broad panel of metabolic and histologic characteristics of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis (NASH) in patients with medically complicated obesity.
Consecutive patients undergoing bariatric surgery were selected for a prospective study. They underwent extensive laboratory and histologic (liver biopsy) assessment, as well as evaluation of rs738409 polymorphism by TaqMan assay.
Only 12 (8.3%) of the 144 patients had normal liver histology, with 72 (50%) NASH, of whom 15 (10.4% of total patients) had fibrosis stage 2-3. PNPLA3 GG genotype correlated positively (P < 0.05) with serum levels of alanine aminotransferase (ALT), asparate aminotransferase (AST), glucose, fibrinogen, and insulin-dependent diabetes mellitus, homeostasis model assessment-insulin resistance, and presence of NASH. Multivariate analysis indicated that PNPLA3 rs738409 G versus C allele remained an (independent) risk factor for NASH, in addition to CK-18 >145 IU/l, glucose >100 mg/dl, and C-reactive protein (CRP) >0.8 mg/dl. The probability of NASH increased from 9% (no risk factor) to 82% if all four risk factors were present.
In this cohort of patients with medically complicated obesity, PNPLA3 rs738409 G allelic expression is associated with hepatic (NASH) and nonhepatic complications of obesity, such as insulin resistance. These novel findings may be related to a greater impact of PNPLA3 variant in magnitude and scope in patients with severe obesity than in less obese populations. Further studies are needed to characterize the nature of these associations.
脂联素(脂肪酶结构域包含蛋白 3,PNPLA3)的等位基因变异(rs738409C→G)与肝脂肪变性和肝纤维化有关。PNPLA3 G 等位基因的生理影响在严重肥胖患者中可能会加剧。在这项研究中,我们研究了 PNPLA3 rs738409 与非酒精性脂肪性肝病和非酒精性脂肪性肝炎(NASH)的广泛代谢和组织学特征在患有医学上复杂肥胖症的患者中的相互作用。
选择接受减肥手术的连续患者进行前瞻性研究。他们接受了广泛的实验室和组织学(肝活检)评估,并通过 TaqMan 分析评估了 rs738409 多态性。
在 144 例患者中,只有 12 例(8.3%)的患者有正常的肝组织学,72 例(50%)为 NASH,其中 15 例(总患者的 10.4%)有 2-3 级纤维化。PNPLA3 GG 基因型与血清丙氨酸氨基转移酶(ALT)、天冬氨酸氨基转移酶(AST)、葡萄糖、纤维蛋白原和胰岛素依赖型糖尿病、稳态模型评估-胰岛素抵抗和 NASH 呈正相关(P <0.05)。多变量分析表明,除 CK-18 >145IU/L、葡萄糖>100mg/dl 和 C 反应蛋白(CRP)>0.8mg/dl 外,PNPLA3 rs738409G 对 C 等位基因仍然是 NASH 的一个(独立)危险因素。如果存在所有四个危险因素,NASH 的概率从 9%(无危险因素)增加到 82%。
在患有医学上复杂肥胖症的患者队列中,PNPLA3 rs738409G 等位基因表达与肝(NASH)和肥胖的非肝并发症有关,如胰岛素抵抗。这些新发现可能与严重肥胖患者中 PNPLA3 变体的影响在程度和范围上比在肥胖程度较轻的人群中更大有关。需要进一步的研究来描述这些关联的性质。